Приказ основних података о документу
Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines
dc.creator | Kokić, Zoran | |
dc.creator | Kon, Predrag | |
dc.creator | Đurković-Đaković, Olgica | |
dc.date.accessioned | 2023-07-18T13:17:02Z | |
dc.date.available | 2023-07-18T13:17:02Z | |
dc.date.issued | 2023 | |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | http://rimi.imi.bg.ac.rs/handle/123456789/1306 | |
dc.description.abstract | The course of the COVID-19 pandemic has been critically altered by the availability of vaccines. To assess the risk of COVID-19 in the vaccinated, as compared to the unvaccinated population, as well as the comparative effectiveness of the BBIBP-CorV (Sinopharm), BNT162b2 (Pfizer/BioNTech), Gam-COVID-Vac (Sputnik V) and ChAdOx1 (AstraZeneca) vaccines in the prevention of clinical infection, we carried out a retrospective study of the incidence of clinical COVID-19 in the Belgrade city municipality of Voždovac among both vaccinated and unvaccinated individuals during a 4-month period between 1 July and 31 October 2021. The study included all individuals with a symptomatic infection confirmed by a positive PCR and/or antigen test. Only those who received two vaccine doses were considered as vaccinated. The results showed that of the Voždovac population of 169,567, a total of 81,447 (48%) individuals were vaccinated by the end of the study. Vaccination coverage increased with age, ranging from 1.06% in those below age 18, to even 78.8% in those above 65 years of age. More than one half (57.5%) of all those vaccinated received BBIBP-CorV, while 25.2% received BNT162b2, 11.7% Gam-COVID-Vac and 5.6% ChAdOx1. The overall risk of infection of the vaccinated vs. the unvaccinated was 0.53 (95% CI 0.45–0.61). Compared to the incidence of COVID-19 of 8.05 per 1000 in the unvaccinated population, the relative risk in the vaccinated was 0.35 (95% CI 0.3–0.41). The overall VE was 65%, differing widely among age groups and by vaccine. VE was 79% for BNT162b2, 62% for BBIBP-CorV, 60% for ChAdOx1 and 54% for Gam-COVID-Vac. The VE for BBIBP-CorV and BNT162b2 increased with age. The obtained results demonstrate a significant overall effectiveness of anti-COVID-19 vaccination, which, however, varied significantly among the analyzed vaccines, and was the highest for BNT162b2. | |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | Vaccines | |
dc.subject | COVID-19 | |
dc.subject | vaccination | |
dc.subject | vaccine effectiveness | |
dc.subject | BBIBP-CorV | |
dc.subject | BNT162b2 | |
dc.subject | Gam-COVID-Vac | |
dc.subject | ChAdOx1 | |
dc.title | Effectiveness of Vaccination in Preventing COVID-19: A Community Study Comparing Four Vaccines | |
dc.type | article | |
dc.rights.license | BY | |
dc.citation.issue | 3 | |
dc.citation.spage | 544 | |
dc.citation.volume | 11 | |
dc.identifier.doi | 10.3390/vaccines11030544 | |
dc.identifier.fulltext | http://rimi.imi.bg.ac.rs/bitstream/id/2968/vaccines-11-00544.pdf | |
dc.type.version | publishedVersion |